This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003:53 Suppl 3:S160-6; discussion S166-9.

doi: 10.1002/ana.10486.

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies

Kenneth Marek¹, Danna Jennings, John Seibyl

Affiliations

PMID: 12666107
DOI: 10.1002/ana.10486

Review

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies

Kenneth Marek et al. Ann Neurol. 2003.

. 2003:53 Suppl 3:S160-6; discussion S166-9.

doi: 10.1002/ana.10486.

Authors

Kenneth Marek¹, Danna Jennings, John Seibyl

Affiliation

¹ Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA. kmarek@indd.org

PMID: 12666107
DOI: 10.1002/ana.10486

No abstract available

PubMed Disclaimer

Similar articles

Imaging end points for monitoring neuroprotection in Parkinson's disease.
Brooks DJ. Brooks DJ. Ann Neurol. 2003;53 Suppl 3:S110-8; discussion S118-9. doi: 10.1002/ana.10480. Ann Neurol. 2003. PMID: 12666103 Review.
Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
Orzi F, Fornai F, Blandini F. Orzi F, et al. Funct Neurol. 2000 Oct-Dec;15(4):269-76. Funct Neurol. 2000. PMID: 11213530 No abstract available.
Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
Frey KA. Frey KA. Eur J Nucl Med Mol Imaging. 2002 May;29(5):715-7. doi: 10.1007/s00259-002-0815-4. Epub 2002 Mar 22. Eur J Nucl Med Mol Imaging. 2002. PMID: 11976814 No abstract available.
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Clarke CE. Clarke CE. Mov Disord. 2004 May;19(5):491-8. doi: 10.1002/mds.20057. Mov Disord. 2004. PMID: 15133811 Review.
Pathophysiology of L-dopa-induced dyskinesias.
Bédard PJ, Blanchet PJ, Lévesque D, Soghomonian JJ, Grondin R, Morissette M, Goulet M, Calon F, Falardeau P, Gomez-Mancilla B, Doucet JP, Robertson GS, DiPaolo T. Bédard PJ, et al. Mov Disord. 1999;14 Suppl 1:4-8. Mov Disord. 1999. PMID: 10493397 Review. No abstract available.

See all similar articles

Cited by

Neuroimaging and therapeutics in movement disorders.
Eckert T, Eidelberg D. Eckert T, et al. NeuroRx. 2005 Apr;2(2):361-71. doi: 10.1602/neurorx.2.2.361. NeuroRx. 2005. PMID: 15897956 Free PMC article. Review.
Impact of subcortical white matter lesions on dopamine transporter SPECT.
Funke E, Kupsch A, Buchert R, Brenner W, Plotkin M. Funke E, et al. J Neural Transm (Vienna). 2013 Jul;120(7):1053-60. doi: 10.1007/s00702-013-0977-1. Epub 2013 Jan 24. J Neural Transm (Vienna). 2013. PMID: 23344720
Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X. Rossi A, et al. Mov Disord. 2018 Jan;33(1):156-159. doi: 10.1002/mds.27063. Epub 2017 Jun 7. Mov Disord. 2018. PMID: 28590580 Free PMC article.
The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.
Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, Bernardi G, Simonetti G, Stanzione P. Schillaci O, et al. Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1452-6. doi: 10.1007/s00259-005-1922-9. Epub 2005 Sep 8. Eur J Nucl Med Mol Imaging. 2005. PMID: 16151764 Clinical Trial.
Changes in network activity with the progression of Parkinson's disease.
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Huang C, et al. Brain. 2007 Jul;130(Pt 7):1834-46. doi: 10.1093/brain/awm086. Epub 2007 Apr 30. Brain. 2007. PMID: 17470495 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information